Association of proton pump inhibitors with the occurrence of gut-derived bacteraemia in patients with haematological malignancy after chemotherapy

References

• Cherif H, Kronvall G, Björkholm M, Kalin M. Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J. 2003;4(6):420–6. doi: 10.1038/sj.thj.6200334
   PubMedGoogle Scholar
• Engelhart S, Glasmacher A, Exner M, Kramer MH. Surveillance for nosocomial infections and fever of unknown origin among adult hematology–oncology patients. Infect Control Hosp Epidemiol. 2002;23(5):244–8. doi: 10.1086/502043
   PubMed Web of Science ®Google Scholar
• Huoi C, Vanhems P, Nicolle MC, Michallet M, Bénet T. Incidence of hospital-acquired pneumonia, bacteraemia and urinary tract infections in patients with haematological malignancies, 2004–2010: a surveillance-based study. PLoS One. 2013;8(3):e58121. doi: 10.1371/journal.pone.0058121.
   PubMed Web of Science ®Google Scholar
• Samonis G, Vardakas KZ, Maraki S, Tansarli GS, Dimopoulou D, Kofteridis DP, et al. A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer. 2013;21(9):2521–6. doi: 10.1007/s00520-013-1816-5
   PubMed Web of Science ®Google Scholar
• Velasco E, Soares M, Byington R, Martins CA, Schirmer M, Dias LM, et al. Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in adult surgical cancer patients. Eur J Clin Microbiol Infect Dis. 2004;23(8):596–602. doi: 10.1007/s10096-004-1181-x
   PubMed Web of Science ®Google Scholar
• Metan G, Demiraslan H, Kaynar LG, Zararsız G, Alp E, Eser B. Factors influencing the early mortality in haematological malignancy patients with nosocomial Gram negative bacilli bacteraemia: a retrospective analysis of 154 cases. Braz J Infect Dis. 2013;17(2):143–9. doi: 10.1016/j.bjid.2012.09.010
   PubMed Web of Science ®Google Scholar
• Chen CY, Tsay W, Tang JL, Tien HF, Chen YC, Chang SC, et al. Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia. Epidemiol Infect. 2010;138(7):1044–51. doi: 10.1017/S0950268809991208
   PubMed Web of Science ®Google Scholar
• Ferrari S, Perut F, Fagioli F, Brach Del Prever A, Meazza C, Parafioriti A, et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed. J Transl Med. 2013;11:268. doi: 10.1186/1479-5876-11-268.
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res. 2010;29:44. doi: 10.1186/1756-9966-29-44.
   PubMed Web of Science ®Google Scholar
• Barletta JF, El-Ibiary SY, Davis LE, Nguyen B, Raney CR. Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection. Mayo Clin Proc. 2013;88(10):1085–90. doi: 10.1016/j.mayocp.2013.07.004
   PubMed Web of Science ®Google Scholar
• Bauer TM, Steinbruckner B, Brinkmann FE, Ditzen AK, Schwacha H, Aponte JJ, et al. Small intestinal bacterial overgrowth in patients with cirrhosis: prevalence and relation with spontaneous bacterial peritonitis. Am J Gastroenterol. 2001;96(10):2962–7. doi: 10.1111/j.1572-0241.2001.04668.x
   PubMed Web of Science ®Google Scholar
• Siple JF, Morey JM, Gutman TE, Weinberg KL, Collins PD. Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites. Ann Pharmacother. 2012;46(10):1413–8. doi: 10.1345/aph.1R174
   PubMed Web of Science ®Google Scholar
• Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut. 1996;39(1):54–9. doi: 10.1136/gut.39.1.54
   PubMed Web of Science ®Google Scholar
• van Vlerken LG, Huisman EJ, van Hoek B, Renooij W, de Rooij FW, Siersema PD, et al. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. Eur J Clin Invest. 2012;42(7):760–7. doi: 10.1111/j.1365-2362.2011.02643.x
   PubMed Web of Science ®Google Scholar
• Parkman HP, Urbain JL, Knight LC, Brown KL, Trate DM, Miller MA, et al. Effect of gastric acid suppressants on human gastric motility. Gut. 1998;42(2):243–50. doi: 10.1136/gut.42.2.243
   PubMed Web of Science ®Google Scholar
• Lewis SJ, Franco S, Young G, O'Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10(4):557–61. doi: 10.1046/j.1365-2036.1996.d01-506.x
   PubMed Web of Science ®Google Scholar
• Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol. 2000;22(2):357–72. doi: 10.3109/08923970009016425
   PubMed Web of Science ®Google Scholar
• Yoshida N, Yoshikawa T, Tanaka Y, Fujita N, Kassai K, Naito Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors – inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(Suppl 1):74–81. doi: 10.1046/j.1365-2036.2000.014s1074.x
   PubMed Web of Science ®Google Scholar
• Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxböck F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30(5):1118–22. doi: 10.1097/00003246-200205000-00026
   PubMed Web of Science ®Google Scholar
• American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011;140(3):1084–91. doi: 10.1053/j.gastro.2011.01.031
   PubMed Web of Science ®Google Scholar
• Laine L, Jensen DM. Management of patients with ulcer bleeding. Am J Gastroenterol. 2012;107(3):345–60; quiz 61. doi: 10.1038/ajg.2011.480
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet. 2009;374(9699):1449–61. doi: 10.1016/S0140-6736(09)60938-7
   PubMed Web of Science ®Google Scholar
• Herzig SJ, Doughty C, Lahoti S, Marchina S, Sanan N, Feng W, et al. Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia. Ann Neurol. 2014;76(5):712–8. doi: 10.1002/ana.24262
   PubMed Web of Science ®Google Scholar
• Proton pump inhibitors: Clostridium difficile infections. Prescrire Int. 2013;22(142):239–40.
   PubMedGoogle Scholar
• Adams AL, Black MH, Zhang JL, Shi JM, Jacobsen SJ. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. Ann Epidemiol. 2014;24(4):286–90. doi: 10.1016/j.annepidem.2014.01.004
   PubMed Web of Science ®Google Scholar
• Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837–44. doi: 10.1038/ki.2014.74
   PubMed Web of Science ®Google Scholar
• Mathieu N. Risk of long-term treatment with proton pump inhibitors. Rev Prat. 2008;58(13):1451–4.
   PubMedGoogle Scholar
• Talley NJ. Risks of proton-pump inhibitors: what every doctor should know. Med J Aust. 2009;190(3):109–10.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther. 2012;36(9):866–74.
   PubMed Web of Science ®Google Scholar
• Goel GA, Deshpande A, Lopez R, Hall GS, van Duin D, Carey WD. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol. 2012;10(4):422–7. doi: 10.1016/j.cgh.2011.11.019
   PubMed Web of Science ®Google Scholar
• Gupta R, Garg P, Kottoor R, Munoz JC, Jamal MM, Lambiase LR, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J. 2010;103(3):207–11. doi: 10.1097/SMJ.0b013e3181ce0e7a
   PubMed Web of Science ®Google Scholar
• Hoffmann F, Glaeske G, Schmiemann G. Increased prescribing of proton pump inhibitors in ambulatory care over the years 2005–2013. Z Gastroenterol. 2015;53(2):95–100.
   PubMed Web of Science ®Google Scholar
• Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25(5):333–40. doi: 10.1046/j.1365-2710.2000.00312.x
   PubMed Web of Science ®Google Scholar
• Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm. 2007;64(13):1396–400. doi: 10.2146/ajhp060393
   PubMed Web of Science ®Google Scholar
• Saltzman JR, Kowdley KV, Pedrosa MC, Sepe T, Golner B, Perrone G, et al. Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. Gastroenterology. 1994;106(3):615–23. doi: 10.1016/0016-5085(94)90693-9
   PubMed Web of Science ®Google Scholar
• Theisen J, Nehra D, Citron D, Johansson J, Hagen JA, Crookes PF, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 2000;4(1):50–4. doi: 10.1016/S1091-255X(00)80032-3
   PubMed Web of Science ®Google Scholar
• Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Ther. 1998;12(1):99–104. doi: 10.1046/j.1365-2036.1998.00275.x
   PubMed Web of Science ®Google Scholar
• Fried M, Siegrist H, Frei R, Froehlich F, Duroux P, Thorens J, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut. 1994;35(1):23–6. doi: 10.1136/gut.35.1.23
   PubMed Web of Science ®Google Scholar
• Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–56; quiz 57. doi: 10.1111/j.1572-0241.2007.01275.x
   PubMed Web of Science ®Google Scholar
• Gatt M, Reddy BS, MacFie J. Review article: bacterial translocation in the critically ill – evidence and methods of prevention. Aliment Pharmacol Ther. 2007;25(7):741–57. doi: 10.1111/j.1365-2036.2006.03174.x
   PubMed Web of Science ®Google Scholar
• Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents. 2008;32(Suppl 1):S30–3. doi: 10.1016/j.ijantimicag.2008.06.017
   PubMedGoogle Scholar